A new study has been launched by the Oxford University on Saturday for assessing safety and immune response of the COVID-19 vaccine in children for the first time.
The aim of this mid stage trial is to determine the effectiveness of the vaccine on children between the age group of 6 and 17.
Further, the process of first inoculation is expected this month with enrollment of around 300 volunteers.
Production Target of AstraZeneca is projected to be 3 billion doses this year with the benchmark of producing over 200 million doses per month by April.
Because of the ease in distribution and economical factor, the two-dose Oxford/AstraZeneca vaccine has been acclaimed as a ‘vaccine for the world’.
These new trials are expected to extend the understanding of control of SARS-CoV2 to younger age groups.
The purpose however is to ensure that these age groups can potentially benefit from inclusion in vaccination programs in the near future.
It could take between six to nine months to produce Covid-19 vaccines that are effective against new variants of the virus.
AstraZeneca’s Covid-19 vaccine, developed jointly with the University of Oxford, has been approved for emergency use in several countries.
Moreover, a version of the vaccine is also being used in India.
The study builds on previous trials of the vaccine, which have shown that it is safe, produces strong immune system responses and has high efficacy in adults.
Earlier, scientists at the Oxford University physics department had developed a COVID-19 test that can identify the virus in 5 minutes or less.
Check all the recent news updates and share market updates